These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 20373365)
1. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression? Soll C; Clavien PA Hepatology; 2010 Apr; 51(4):1113-5. PubMed ID: 20373365 [No Abstract] [Full Text] [Related]
2. [Liver transplantation for hepatocellular carcinoma and potential application of PSI]. Decaens T; Duvoux C Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332 [TBL] [Abstract][Full Text] [Related]
3. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma. Subbiah IM; Brown RE; Fallon MB Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964 [No Abstract] [Full Text] [Related]
4. Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Schnitzbauer AA; Schlitt HJ; Geissler EK Transplantation; 2011 Jun; 91(11):1173-6. PubMed ID: 21427632 [TBL] [Abstract][Full Text] [Related]
5. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? Schwartz M; Roayaie S; Llovet J J Hepatol; 2005 Oct; 43(4):584-9. PubMed ID: 16120468 [No Abstract] [Full Text] [Related]
10. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Bhatia S; Thompson JA Adv Ther; 2009 Jan; 26(1):55-67. PubMed ID: 19172239 [TBL] [Abstract][Full Text] [Related]
11. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma. Huynh H Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis B recurrence in relation to immunosuppression and acute allograft rejection. Platz KP; Mueller AR; Haller GW; Naumann U; Berg T; Fukomoto T; Lemmens HP; Hopf U; Lobeck H; Neuhaus P Transplant Proc; 1996 Dec; 28(6):3236-7. PubMed ID: 8962252 [No Abstract] [Full Text] [Related]
13. Long-term follow-up in hepatitis C patients with respect to immunosuppression. Mueller AR; Platz KP; Berg T; Fukomoto T; Guckelberger O; Neuhaus R; Bechstein WO; Hopf U; Lobeck H; Neuhaus P Transplant Proc; 1996 Dec; 28(6):3241-2. PubMed ID: 8962255 [No Abstract] [Full Text] [Related]
14. Analysis of risk factors for recurrence of hepatocellular carcinoma after orthotopic liver transplantation. Lohmann R; Bechstein WO; Langrehr JM; Knoop M; Lobeck H; Keck H; Lemmems HP; Blumhardt G; Neuhaus P Transplant Proc; 1995 Feb; 27(1):1245-6. PubMed ID: 7533376 [No Abstract] [Full Text] [Related]
15. Should we expand the criteria for hepatocellular carcinoma with living-donor liver transplantation?--no, never. Hiatt JR; Carmody IC; Busuttil RW J Hepatol; 2005 Oct; 43(4):573-7. PubMed ID: 16112768 [No Abstract] [Full Text] [Related]
16. Liver transplantation and hepatocellular carcinoma biology: beginning of the end of the era of educated guesses. Vauthey JN; Ajani JA J Clin Oncol; 2003 Dec; 21(23):4265-7. PubMed ID: 14581443 [No Abstract] [Full Text] [Related]
17. Should we expand the criteria for liver transplantation for hepatocellular carcinoma--yes, of course! Broelsch CE; Frilling A; Malago M J Hepatol; 2005 Oct; 43(4):569-73. PubMed ID: 16120470 [No Abstract] [Full Text] [Related]